Newtyn Partners, L.P., Director Other at MERRIMACK PHARMACEUTICALS INC (MACK), bought 25,658 shares at $4.48 ($116K) on 2022-01-28, disclosed to the SEC on 2022-02-01.
Open-market purchase of $116k MACK by Director Other. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history). Context: insider career grade B.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $4.48 | 1,505 | $7K | 5.8% |
| 2 | $4.48 | 11,458 | $51K | 44.4% |
| 3 | $4.48 | 11,458 | $51K | 44.4% |
| 4 | $5.05 | 523 | $3K | 2.3% |
| 5 | $5.05 | 714 | $4K | 3.1% |
| Total | $4.51 avg | 25,658 |
| $116K |
| 100% |
| Filing → |
| MACK | BUY | 2022-06-16 | $186K | — | Filing → |
| MACK | BUY | 2020-11-27 | $504K | — | Filing → |